Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GMTX NYSE:RCUS NASDAQ:SANA NASDAQ:TNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMTXGemini Therapeutics$68.08+1.2%$68.17$1.16▼$14.10$2.95B-0.12189,291 shs219,645 shsRCUSArcus Biosciences$23.85+2.4%$24.05$7.91▼$28.72$2.93B0.851.00 million shs1.45 million shsSANASana Biotechnology$2.68-3.2%$3.22$2.41▼$6.55$770.87M2.143.70 million shs2.25 million shsTNGXTango Therapeutics$30.94+3.8%$23.46$4.40▼$32.79$4.31B1.194.43 million shs9.96 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMTXGemini Therapeutics-1.59%-4.41%-2.86%+12.53%+26.72%RCUSArcus Biosciences+5.02%-5.90%-6.25%+6.58%+157.20%SANASana Biotechnology-1.77%-6.42%-15.03%-17.56%+2.59%TNGXTango Therapeutics+3.97%+34.63%+26.89%+72.37%+529.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMTXGemini Therapeutics$68.08+1.2%$68.17$1.16▼$14.10$2.95B-0.12189,291 shs219,645 shsRCUSArcus Biosciences$23.85+2.4%$24.05$7.91▼$28.72$2.93B0.851.00 million shs1.45 million shsSANASana Biotechnology$2.68-3.2%$3.22$2.41▼$6.55$770.87M2.143.70 million shs2.25 million shsTNGXTango Therapeutics$30.94+3.8%$23.46$4.40▼$32.79$4.31B1.194.43 million shs9.96 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMTXGemini Therapeutics-1.59%-4.41%-2.86%+12.53%+26.72%RCUSArcus Biosciences+5.02%-5.90%-6.25%+6.58%+157.20%SANASana Biotechnology-1.77%-6.42%-15.03%-17.56%+2.59%TNGXTango Therapeutics+3.97%+34.63%+26.89%+72.37%+529.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMTXGemini Therapeutics 0.00N/AN/AN/ARCUSArcus Biosciences 2.58Moderate Buy$35.1047.17% UpsideSANASana Biotechnology 2.67Moderate Buy$9.50254.48% UpsideTNGXTango Therapeutics 2.71Moderate Buy$38.4224.17% UpsideCurrent Analyst Ratings BreakdownLatest SANA, TNGX, RCUS, and GMTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2026TNGXTango Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.00 ➝ $66.006/9/2026TNGXTango Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $42.006/8/2026TNGXTango Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$36.006/8/2026TNGXTango Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetPeer Perform ➝ Outperform$35.006/8/2026TNGXTango Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/8/2026TNGXTango Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$55.00 ➝ $69.006/8/2026TNGXTango Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradePeer Perform ➝ Outperform6/4/2026RCUSArcus Biosciences Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$46.005/28/2026TNGXTango Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/18/2026RCUSArcus Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.00 ➝ $35.005/15/2026TNGXTango Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$20.00 ➝ $30.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/ARCUSArcus Biosciences$247M12.14N/AN/A$5.84 per share4.08SANASana BiotechnologyN/AN/AN/AN/A$0.60 per shareN/ATNGXTango Therapeutics$62.38M71.75N/AN/A$2.57 per share12.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/ARCUSArcus Biosciences-$353M-$3.18N/AN/AN/A-156.36%-68.97%-35.27%8/5/2026 (Estimated)SANASana Biotechnology-$244.17M-$0.93N/AN/AN/AN/A-108.01%-40.68%8/10/2026 (Estimated)TNGXTango Therapeutics-$101.59M-$0.83N/AN/AN/A-151.15%-41.54%-33.44%8/4/2026 (Estimated)Latest SANA, TNGX, RCUS, and GMTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026TNGXTango Therapeutics-$0.32-$0.32N/A-$0.32$0.58 millionN/A5/11/2026Q1 2026SANASana Biotechnology-$0.15-$0.14+$0.01-$0.17N/AN/A5/5/2026Q1 2026RCUSArcus Biosciences-$0.92-$1.02-$0.10-$1.02$29.49 million$17.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGMTXGemini TherapeuticsN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/AN/ATNGXTango TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMTXGemini TherapeuticsN/A71.4971.49RCUSArcus Biosciences0.194.044.04SANASana BiotechnologyN/A1.291.29TNGXTango TherapeuticsN/A27.3827.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMTXGemini Therapeutics75.42%RCUSArcus Biosciences92.89%SANASana Biotechnology88.23%TNGXTango Therapeutics78.99%Insider OwnershipCompanyInsider OwnershipGMTXGemini Therapeutics12.90%RCUSArcus Biosciences9.60%SANASana Biotechnology25.40%TNGXTango Therapeutics6.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableRCUSArcus Biosciences500125.77 million113.70 millionOptionableSANASana Biotechnology380278.29 million207.61 millionOptionableTNGXTango Therapeutics90144.65 million135.25 millionOptionableSANA, TNGX, RCUS, and GMTX HeadlinesRecent News About These CompaniesIs Tango Therapeutics (TNGX) Price Justified After Its 7x Surge In One YearJune 10 at 8:15 PM | finance.yahoo.comTango Therapeutics Announces Major Underwritten Equity OfferingJune 10 at 7:10 PM | tipranks.comTango Therapeutics Announces Pricing of $600 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsJune 9 at 11:11 PM | quiverquant.comQTango Therapeutics Announces Pricing of $600 Million Upsized Public OfferingJune 9 at 10:49 PM | globenewswire.comTango Therapeutics: Combo Data With Revolution's RAS Inhibitor Whets Risk AppetiteJune 9 at 3:10 PM | seekingalpha.comTango Therapeutics (TNGX) stock soars on pancreatic cancer trial resultsJune 9 at 2:51 PM | msn.comTNGX Stock Jumps 53% on Early Pancreatic Cancer Study ResultsJune 9 at 1:46 PM | zacks.comTango shares surge on early pancreatic cancer combination dataJune 9 at 9:51 AM | thepharmaletter.comTTango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancreatic Cancer TranscriptJune 8, 2026 | seekingalpha.comTango Therapeutics stock soars on promising pancreatic cancer dataJune 8, 2026 | invezz.comITango Therapeutics Announces Proposed $500 Million Public OfferingJune 8, 2026 | globenewswire.comTango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancreatic Cancer - SlideshowJune 8, 2026 | seekingalpha.comTango Therapeutics stock soars on promising pancreatic cancer dataJune 8, 2026 | invezz.comIStock Movers: Intel, Tango Therapeutics, StrategyJune 8, 2026 | bloomberg.comTNGX stock hits all-time high – Wolfe Research calls Tango Therapeutic’s pancreatic cancer trial data ‘groundbreaking’June 8, 2026 | msn.comTango Therapeutics Stock Soars 42% After 'Unprecedented' Data on Pancreatic Cancer TreatmentJune 8, 2026 | barrons.comTango skyrockets 47% on eye-popping pancreatic cancer resultsJune 8, 2026 | msn.comTango Therapeutics' pancreatic cancer drug combo shows promise in studyJune 8, 2026 | reuters.comTango Therapeutics Reports Encouraging Initial Phase 1/2 Data on Vopimetostat and Daraxonrasib Combination for Treatment of MTAP-Deleted Pancreatic CancerJune 8, 2026 | quiverquant.comQTango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic CancerJune 8, 2026 | globenewswire.comVanguard Group Inc. Has $59.81 Million Holdings in Tango Therapeutics, Inc. $TNGXMay 15, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSANA, TNGX, RCUS, and GMTX Company DescriptionsGemini Therapeutics NASDAQ:GMTX$68.08 +0.83 (+1.23%) As of 06/11/2026Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.Arcus Biosciences NYSE:RCUS$23.85 +0.55 (+2.36%) Closing price 03:59 PM EasternExtended Trading$23.93 +0.08 (+0.34%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.Sana Biotechnology NASDAQ:SANA$2.68 -0.09 (-3.25%) Closing price 04:00 PM EasternExtended Trading$2.70 +0.02 (+0.75%) As of 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.Tango Therapeutics NASDAQ:TNGX$30.94 +1.12 (+3.76%) Closing price 04:00 PM EasternExtended Trading$30.82 -0.12 (-0.38%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
